Intongkam S, et al. - A longitudinal open-label study was carried out in 46 RA individuals in order to evaluate the efficiency and safety of the hepatitis B vaccination in RA persons receiving conventional and/or biological disease-modifying antirheumatic drugs (DMARDs). Seroprotection was lower in the RA individuals vs controls. In persons vs controls who were receiving biological DMARDs and conventional DMARDs, a lower proportion of seroprotection was noticed. The rate of RA flare was not extended following hepatitis B vaccination. In conclusion, in comparison with controls, individuals with RA receiving DMARDs had a less humoral response to hepatitis B vaccination. Aging and rituximab use was related to impaired response to hepatitis B vaccination. Moreover, in RA individuals, hepatitis B vaccination was safe and well-tolerated.